哮喘中的生物制剂：生物标志物的作用

IF 2.7 3区医学 Q2 ALLERGY

Immunology and Allergy Clinics of North America Pub Date : 2024-09-02 DOI:10.1016/j.iac.2024.08.003

引用次数: 0

摘要

我们对哮喘的现代认识主要涉及炎症内型的识别，以指导治疗。这种区别主要涉及 2 型炎症的识别，不同的生物标志物已被很好地描述。血液中的嗜酸性粒细胞证实了白细胞介素（IL）-5 轴的活动，而呼出一氧化氮的比例则表明了 IL-4/IL-13 轴的活动，从而为我们提供了这些不同但互补的途径的活动迹象。这些生物标志物可预测疾病的活动性，当生物标志物升高时，病情恶化的风险会增加，当两者都升高时，病情恶化的风险会成倍增加。血清免疫球蛋白 E 也与这一通路有关，可以代表与过敏原相关的刺激。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Biologics in Asthma

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Immunology and Allergy Clinics of North America 医学-过敏

CiteScore

5.40

自引率

3.80%

发文量

审稿时长

>12 weeks

期刊介绍： Immunology and Allergy Clinics of North America updates you on the latest trends in patient management; keeps you up to date on the newest advances; and provides a sound basis for choosing treatment options. Each issue focuses on a single topic in immunology and allergy and is presented under the direction of an experienced guest editor. Topics include allergens, immunotherapy, anaphylaxis, asthma, drug allergy, eosinophilrelated disorders, food allergy, immunodeficiency states (non-HIV), basic science, mast cell disorders, rhinitis and sinusitis, and urticaria and angioedema. Immunology and Allergy Clinics of North America is published four times each year, in February, May, August, and November.